Abstract:Background and purpose: We sought to understand why (-)-cannabidiol (CBD) and (-)-cannabidiol-dimethylheptyl (CBD-DMH) exhibit distinct pharmacology, despite near identical structures. Experimental approach: HEK293A cells expressing either human type 1 cannabinoid (CB1 ) receptors or CB2 receptors were treated with CBD or CBD-DMH with or without the CB1 and CB2 receptor agonist CP55,940, CB1 receptor allosteric modulator Org27569 or CB2 receptor inverse agonist SR144528. Ligand binding, cAMP levels and βarrestin1 recruitment were measured. CBD and CBD-DMH binding was simulated with models of human CB1 or CB2 receptors, based on the recently published crystal structures of agonist-bound (5XRA) or antagonist-bound (5TGZ) human CB1 receptors. Key results: At CB1 receptors, CBD was a negative allosteric modulator (NAM), and CBD-DMH was a mixed agonist/positive allosteric modulator. CBD and Org27569 shared multiple interacting residues in the antagonist-bound model of CB1 receptors (5TGZ) but shared a binding site with CP55,940 in the agonist-bound model of CB1 receptors (5XRA). The binding site for CBD-DMH in the CB1 receptor models overlapped with CP55,940 and Org27569. At CB2 receptors, CBD was a partial agonist, and CBD-DMH was a positive allosteric modulator of cAMP modulation but a NAM of βarrestin1 recruitment. CBD, CP55,940 and SR144528 shared a binding site in the CB2 receptor models that was separate from CBD-DMH. Conclusion and implications: The pharmacological activity of CBD and CBD-DMH in HEK293A cells and their modelled binding sites at CB1 and CB2 receptors may explain their in vivo effects and illuminates the difficulties associated with the development of allosteric modulators for CB1 and CB2 receptors. Linked articles: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

The future of type 1 cannabinoid receptor allosteric ligands

Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1

New Insights in Cannabinoid Receptor Structure and Signaling

In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Structure of an allosteric modulator bound to the CB1 cannabinoid receptor

Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies

Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.

Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain

Latest Advances in Novel Cannabinoid CB2 Ligands for Drug Abuse and Their Therapeutic Potential

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors

GPCR Allostery: A View from Computational Biology.

Protein Allostery in Drug Discovery

Harnessing Allostery: a Novel Approach to Drug Discovery.

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs

Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery